Hamostat Injection
Aminocaproic Acid
Samarth Life Sciences Pvt Ltd
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 135.49 NPR |
Indications
Hamostat Injection is used for:
Haemorrhage, Missed abortion, Hereditary hemorrhagic telangiectasia,Traumatic hyphema, Dental bleeding, Hemophilia A, Postoperative bleeding, Systemic hyperfibrinolysis
Adult Dose
Intravenous
Treatment and prophylaxis of haemorrhage
Adult: Initially, 4-5 g as a 2% solution over 1 hr followed by a 1 g/hr infusion continued for up to 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr.
Oral
Treatment and prophylaxis of haemorrhage
Adult: Initially, 4-5 g, followed by 1-1.25 g every hr for about 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr.
Patients with haemophilia undergoing dental extraction
Adult: Initially, 6 g immediately after the procedure, followed by 6 g every 6 hr for up to 10 days.
Child Dose
Renal Dose
Renal impairment: Dosage reduction may be required.
Administration
IV Administration
Initial 5 g in 250 mL over 1 hr, each subsequent gram in 50-100 mL at 1 g/hr
Rapid injection undiluted into a vein is not recommended
Continue for about 8 hr or until bleeding has been controlled
Oral
May be taken with or without food. May be taken w/ meals to prevent GI upset.
Contra Indications
Bleeding due to disseminated intravascular coagulation. Rapid IV administration.
Precautions
Renal or cardiac disorders. Urinary tract bleeding, haematuria of upper urinary tract origin; veno-occlusive hepatic disease, skeletal myopathy, neonates. Monitor creatinine phosphokinase. Avoid admin with factor IX complex concentrates. Pregnancy and lactation.
Lactation: not known whether excreted in breast milk, use caution
Pregnancy-Lactation
Interactions
Increased risk of hypercoagulability with OC and oestrogens.
Adverse Effects
Side effects of Aminocaproic Acid :
Oedema, headache, malaise, allergic and anaphylactic reactions, anaphylaxis, bradycardia, hypotension, peripheral ischaemia, thrombosis, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, coagulation disorder, leukopaenia, thrombocytopaenia, increased CPK, muscle damage, myalgia, myopathy, myositis, rhabdomyolysis, confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope, dyspnoea, nasal congestion, pulmonary embolism, pruritus, rash, tinnitus, decreased vision, watery eyes, increased BUN, dry ejaculation.
Potentially Fatal: Cardiac and hepatic damage.
Mechanism of Action
Aminocaproic acid inhibits the action of plasminogen activators and, to a lesser extent, it also has some antiplasmin activity.
Note
Hamostat Injection manufactured by Samarth Life Sciences Pvt Ltd. Its generic name is Aminocaproic Acid. Hamostat is availble in Nepal.
Farmaco Nepal drug index information on Hamostat Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.